Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Emergent BioSolutions

Tracked across 3 events · 21 articles · First seen Apr 29, 2026 · Last active Sep 10, 2026

Sentiment
-33
Attention
2
Events
3
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
2 -60
Regulatory
Impact: Emergent BioSolutions is the subject of the investigation. The company reduced its FY2026 revenue and EBITDA guidance and recorded a $191.3 million impairment on Naloxone, leading to a sharp stock decline and potential legal liabilities.
Aug 10, 2026 · 6 articles
2 -60
Regulatory
Pomerantz LLP LLP announced it is investigating claims on behalf of investors of Emergent BioSolutions Inc. concerning whether the company and certain of its officers and/or directors engaged in securities fraud or other unlawful business…
Impact: Emergent is the subject of the securities fraud investigation and the company whose impairment charge, guidance cut, and 29.58% stock drop triggered it. The probe raises the risk of litigation costs and further reputational damage.
Aug 25, 2026 · 8 articles
2 20
Business
Impact: Emergent BioSolutions, the manufacturer of Narcan (naloxone) nasal spray, partnered with Davis Schneider to promote awareness and availability of naloxone, potentially increasing its market reach and public perception.
Apr 29, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Emergent BioSolutions live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.